Skip to content

Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery

A Randomized, Single-Blinded, Sham-Controlled Study Evaluating the Efficacy and Safety of RELAY, a Device Enabling Both Local Anesthetic Delivery and Neuromodulation Following Shoulder or Foot Surgery: Single Arm Training Run-In Phase

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06818708
Enrollment
20
Registered
2025-02-10
Start date
2025-03-20
Completion date
2025-06-26
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle Arthropathy, Hallux Valgus, Rotator Cuff Injuries, Shoulder Disease

Brief summary

Postoperative pain remains undertreated with inadequate analgesic options. Opioids have well-known limitations for both individuals and society; single-injection and continuous peripheral nerve blocks provide intense analgesia but are limited in duration to 24-72 hours; and current neuromodulation options-with a duration measured in weeks and not hours-are prohibitively expensive and require an additional procedure. One possible solution is a device currently under investigation to treat postoperative pain. The RELAY system (Gate Science, Moultonborough, New Hampshire) is comprised of a basic catheter-over-needle device to allow administration of a single-injection of local anesthetic via the needle (or catheter) followed by a perineural local anesthetic infusion via the remaining catheter (when desired). Subsequent to the local anesthetic administration, instead of removing the catheter as with all previous continuous peripheral nerve block equipment, electric current may be delivered via the same catheter and an integrated pulse generator for up to 28 days. This is potentially revolutionary because it would allow an anesthesiologist to deliver (1) a single-injection peripheral nerve block; (2) a continuous peripheral nerve block; and (3) neuromodulation using a single device that can theoretically be placed in the same amount of time required for a single-injection peripheral nerve block. Instead of providing fewer than 24 hours of postoperative analgesia, up to 28 days of pain control could be delivered without disruption of existing practice patterns. The ultimate objective of the proposed investigation is to prepare for a randomized clinical trial investigating the use of the RELAY device to provide postoperative analgesia. This feasibility study will be a series of participants all receiving both local anesthetic and electric current via a single device (RELAY, Gate Science, Moultonborough, New Hampshire). The purpose will be to optimize the insertion approach and stimulation administration during the first 7 days following foot and shoulder surgery as well as training the clinical investigators.

Detailed description

Specific Aim: To determine the feasibility and optimize the protocol for the RELAY device following foot and shoulder surgery to prepare for the subsequent randomized, controlled pilot study. For individuals of childbearing potential, a sample of urine will be collected before any study interventions to confirm a non-pregnant state (this is standard procedure for all surgical patients). The RELAY device combines a catheter-over-needle to permit ultrasound-guided percutaneous insertion with the tip adjacent to a peripheral nerve or plexus, followed by needle removal which leaves the catheter in situ to deliver a bolus of local anesthetic (if desired) and subsequent perineural local anesthetic infusion (if desired). The catheter also has 3 integrated electrodes to enable neuromodulation using the integrated pulse generator and battery. Participants will have standard external monitors placed and oxygen delivered by facemask or nasal cannula. The peripheral nerve block site(s) will be cleansed with chlorhexidine gluconate and isopropyl alcohol. Intravenous sedation/analgesia with midazolam and/or fentanyl will be titrated for patient comfort as is standard for peripheral nerve block administration. The nerves treated will include the sciatic proximal to the popliteal crease for foot surgery and the brachial plexus for shoulder surgery. The target nerve(s) will be visualized with ultrasound using a transverse cross-sectional (short axis) view and a skin wheal of local anesthetic will be raised inferior to the transducer to anesthetize the skin and then the track towards the target. The RELAY with the integrated needle will be inserted adjacent to the target nerve with an in-plane approach. Dextrose 5% in water (1-20 mL) will be injected via the needle to open a space around the target nerve(s), the catheter advanced, and the needle subsequently withdrawn. Electrical current will be introduced with increasing intensity via each of the anode electrodes to optimize participant's perceived stimulation (control provided by the Gate Keeper app from an investigator's phone or tablet). Accurate lead placement will be confirmed with subject reports of comfortable sensations over the surgical site without eliciting muscle contractions. The minimum threshold and maximum comfortable amplitudes will be determined along with the optimal frequency, pulse duration, and anode/cathode. Starting from the lowest possible current the investigators increase the current until the participant states that they feel a buzzing sensation (some describe it as a comfortable massage). That is the minimal sensed current. The investigators then continue increasing with the instructions to let us know when it starts to be less comfortable-and to stop us before it hurts. That is the maximum comfortable current. The stimulator will be then set to deliver the minimum threshold amplitude and turned off for surgery. The pulse generator of the RELAY has a frequency between 1-250 Hz, a pulse duration of 1-200 µs, and a current of 0.001-10 mA (1-10,000 µA). The investigators will maximize frequency, minimize pulse duration, and have participants adjust the amplitude following surgery, as needed. Local anesthetic (10 mL of lidocaine 2% with epinephrine) will be injected with negative aspiration every 3 mL and resulting sensory block confirmed to ensure accurate catheter tip placement. Following block confirmation (sensory deficits in the expected nerve distributions), the RELAY will be affixed with both surgical adhesive (2-Octyl 2-cyanoacrylate) at the entry site and a chlorohexidine-impregnated occlusive dressing \[research specific\]. Subsequently, 10 mL of bupivacaine 0.5% with epinephrine will be injected negative aspiration every 3 mL along with a supplemental single-injection saphenous nerve block for foot/ankle surgery. Intraoperatively, surgeons will be permitted to infiltrate the surgical area with long-acting local anesthetic as their common practice dictates. Postoperatively, the stimulators will be connected to participants' phones and turned on. If a patient's surgeon requests a postoperative continuous peripheral nerve block, a ropivacaine 0.2% infusion will be provided per standard UC San Diego protocol. After 7 days, participants themselves or their caretaker will remove the occlusive dressing and withdraw the catheter (and integrated electrodes) with gentle traction and rotation at home. The devices are single-use and disposable.

Interventions

Percutaneous peripheral nerve stimulation with a frequency between 1-250 Hz, a pulse duration of 1-200 µs, and a current of 0.001-10 mA (1-10,000 µA). If the same pattern holds for the RELAY device as for previously tested peripheral nerve stimulators, we will maximize frequency, minimize pulse duration, and have participants adjust the amplitude, as needed.

Sponsors

Gate Science
CollaboratorINDUSTRY
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

A series of participants all receiving active treatment

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult participants of at least 18 years of age 2. Undergoing a rotator cuff repair, total shoulder arthroplasty, ankle arthroplasty/arthrodesis, or foot surgery anticipated to result in moderate-to-severe pain for at least one week 3. Planned single-injection peripheral nerve block(s) 4. An Android or Apple smartphone able to download the Gate Keeper controller app

Exclusion criteria

1. Chronic opioid or tramadol use (daily within prior 2 weeks and duration \> 4 weeks) 2. Neuro-muscular deficit of the surgical limb 3. Compromised immune system based on medical history (e.g., immunosuppressive therapies such as chemotherapy, radiation, sepsis, infection), or other conditions that places the subject at increased risk of infection 4. Implanted spinal cord stimulator, cardiac pacemaker/defibrillator, deep brain stimulator, or other implantable neurostimulator whose stimulus current pathway may overlap 5. History of bleeding disorder 6. Antiplatelet or anticoagulation therapies other than aspirin 7. Allergy to skin-contact materials (occlusive dressings, bandages, tape etc.) 8. Incarceration 9. Pregnancy 10. Moderate pain (NRS \> 3) in an anatomic location other than the surgical site 11. Anxiety disorder 12. History of substance misuse 13. Inability to communicate with the investigators 14. Inability to contact the investigators during the treatment period, and vice versa (e.g., lack of telephone access) 15. Allergy to amide local anesthetics 16. Morbid obesity (body mass index \> 40 kg/m2)

Design outcomes

Primary

MeasureTime frameDescription
Average Daily Pain Intensity 1st WeekDays 1-4 and 7The median of 5 daily average pain intensity scores for Days 1-4 and 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Secondary

MeasureTime frameDescription
Brief Pain Inventory (Interference Sub Scale) Day 3Postoperative day 3The Brief pain Inventory (short form) is an instrument specifically designed to assess pain and its impact on physical and emotional functioning. The brief Inventory is comprised of three domains: (1) pain, with four questions involving worst, average and current pain levels using a 0-10 numeric rating scale; (2) percentage of relief provided by pain treatments with one question \[reported score is the percentage divided by 10 and then subtracted from 10: 0=complete relief,10=no relief\] and, (3) interference with 7 questions involving physical and emotional functioning using a 0-10 Likert scale \[0=no interference;10=complete interference\]: general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. This outcome will include solely the interference subscale with a minimum score of 0 (optimal outcome) and maximum score of 70 (worst possible outcome).
Brief Pain Inventory (Interference Sub Scale) Day 7Postoperative day 7The Brief pain Inventory (short form) is an instrument specifically designed to assess pain and its impact on physical and emotional functioning. The brief Inventory is comprised of three domains: (1) pain, with four questions involving worst, average and current pain levels using a 0-10 numeric rating scale; (2) percentage of relief provided by pain treatments with one question \[reported score is the percentage divided by 10 and then subtracted from 10: 0=complete relief,10=no relief\] and, (3) interference with 7 questions involving physical and emotional functioning using a 0-10 Likert scale \[0=no interference;10=complete interference\]: general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. This outcome will include solely the interference subscale with a minimum score of 0 (optimal outcome) and maximum score of 70 (worst possible outcome).
Worst Daily Pain Intensity 1st WeekDays 1-4 and 7The median of 5 daily worst (maximum) pain intensity scores for Days 1-4 and 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)
Awakenings Due to Pain 1st WeekCollected on postoperative days 1, 2, 3, 4, and 7Cumulative number of nightly awakenings due to pain
Average Daily Pain Intensity Day 7Day 7The average pain intensity score on Day 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)
Cumulative Opioid Use 1st WeekThe first 7 days following surgeryThe cumulative opioid use measured in oxycodone equivalents during the first 7 days following surgery
Opioid Consumption Day 7Day 7The cumulative opioid use from the previous 24 hours measured in oxycodone equivalents as recorded on Day 7
Daily Average Pain Intensitypostoperative Days 1, 2, 3, 4, 7, 8 and 14The average pain intensity score on each postoperative day as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)
Daily Worst Pain Intensitypostoperative Days 1, 2, 3, 4, 7, 8 and 14The worst pain intensity score on each postoperative day as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)
Daily Opioid Consumptionpostoperative Days 1, 2, 3, 4, 7, 8 and 14The cumulative opioid use from the previous 24 hours measured in oxycodone equivalents as recorded on Days 1-4, 7, 8, and 14
Worst (Maximum) Daily Pain Intensity Day 7Day 7The worst pain intensity score on Day 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Countries

United States

Participant flow

Participants by arm

ArmCount
Experimental Treatment
RELAY catheter will be inserted under ultrasound guidance followed by a local anesthetic bolus injection. If a patient's surgeon requests a postoperative continuous peripheral nerve block, a ropivacaine 0.2% infusion will be initiated in the recovery room. Within the recovery room, the stimulators will be connected to participants' phones and turned on. The catheters will be removed on postoperative day 7. Experimental Treatment: Percutaneous peripheral nerve stimulation with a frequency between 1-250 Hz, a pulse duration of 1-200 µs, and a current of 0.001-10 mA (1-10,000 µA). If the same pattern holds for the RELAY device as for previously tested peripheral nerve stimulators, we will maximize frequency, minimize pulse duration, and have participants adjust the amplitude, as needed.
20
Total20

Baseline characteristics

CharacteristicExperimental Treatment
Age, Continuous57 years
STANDARD_DEVIATION 14
Body Mass Index30 kg/m^2
STANDARD_DEVIATION 6
Height173 cm
STANDARD_DEVIATION 9
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
11 Participants
Weight (kg)87 kg
STANDARD_DEVIATION 20

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
5 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Average Daily Pain Intensity 1st Week

The median of 5 daily average pain intensity scores for Days 1-4 and 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Time frame: Days 1-4 and 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentAverage Daily Pain Intensity 1st Week2 units on a scale
Secondary

Average Daily Pain Intensity Day 7

The average pain intensity score on Day 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Time frame: Day 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentAverage Daily Pain Intensity Day 70 units on a scale
Secondary

Awakenings Due to Pain 1st Week

Cumulative number of nightly awakenings due to pain

Time frame: Collected on postoperative days 1, 2, 3, 4, and 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentAwakenings Due to Pain 1st Week2 number of awakenings
Secondary

Brief Pain Inventory (Interference Sub Scale) Day 3

The Brief pain Inventory (short form) is an instrument specifically designed to assess pain and its impact on physical and emotional functioning. The brief Inventory is comprised of three domains: (1) pain, with four questions involving worst, average and current pain levels using a 0-10 numeric rating scale; (2) percentage of relief provided by pain treatments with one question \[reported score is the percentage divided by 10 and then subtracted from 10: 0=complete relief,10=no relief\] and, (3) interference with 7 questions involving physical and emotional functioning using a 0-10 Likert scale \[0=no interference;10=complete interference\]: general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. This outcome will include solely the interference subscale with a minimum score of 0 (optimal outcome) and maximum score of 70 (worst possible outcome).

Time frame: Postoperative day 3

ArmMeasureValue (MEDIAN)
Experimental TreatmentBrief Pain Inventory (Interference Sub Scale) Day 32 units on a scale
Secondary

Brief Pain Inventory (Interference Sub Scale) Day 7

The Brief pain Inventory (short form) is an instrument specifically designed to assess pain and its impact on physical and emotional functioning. The brief Inventory is comprised of three domains: (1) pain, with four questions involving worst, average and current pain levels using a 0-10 numeric rating scale; (2) percentage of relief provided by pain treatments with one question \[reported score is the percentage divided by 10 and then subtracted from 10: 0=complete relief,10=no relief\] and, (3) interference with 7 questions involving physical and emotional functioning using a 0-10 Likert scale \[0=no interference;10=complete interference\]: general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. This outcome will include solely the interference subscale with a minimum score of 0 (optimal outcome) and maximum score of 70 (worst possible outcome).

Time frame: Postoperative day 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentBrief Pain Inventory (Interference Sub Scale) Day 70 units on a scale
Secondary

Cumulative Opioid Use 1st Week

The cumulative opioid use measured in oxycodone equivalents during the first 7 days following surgery

Time frame: The first 7 days following surgery

ArmMeasureValue (MEDIAN)
Experimental TreatmentCumulative Opioid Use 1st Week43 milligrams
Secondary

Daily Average Pain Intensity

The average pain intensity score on each postoperative day as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Time frame: postoperative Days 1, 2, 3, 4, 7, 8 and 14

ArmMeasureGroupValue (MEDIAN)
Experimental TreatmentDaily Average Pain IntensityDay 13 units on a scale
Experimental TreatmentDaily Average Pain IntensityDay 22 units on a scale
Experimental TreatmentDaily Average Pain IntensityDay 32 units on a scale
Experimental TreatmentDaily Average Pain IntensityDay 41 units on a scale
Experimental TreatmentDaily Average Pain IntensityDay 70 units on a scale
Experimental TreatmentDaily Average Pain IntensityDay 80 units on a scale
Experimental TreatmentDaily Average Pain IntensityDay 140 units on a scale
Secondary

Daily Opioid Consumption

The cumulative opioid use from the previous 24 hours measured in oxycodone equivalents as recorded on Days 1-4, 7, 8, and 14

Time frame: postoperative Days 1, 2, 3, 4, 7, 8 and 14

ArmMeasureGroupValue (MEDIAN)
Experimental TreatmentDaily Opioid ConsumptionDay 10.3 milligrams
Experimental TreatmentDaily Opioid ConsumptionDay 20 milligrams
Experimental TreatmentDaily Opioid ConsumptionDay 30 milligrams
Experimental TreatmentDaily Opioid ConsumptionDay 40 milligrams
Experimental TreatmentDaily Opioid ConsumptionDay 70 milligrams
Experimental TreatmentDaily Opioid ConsumptionDay 80 milligrams
Experimental TreatmentDaily Opioid ConsumptionDay 140 milligrams
Secondary

Daily Worst Pain Intensity

The worst pain intensity score on each postoperative day as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Time frame: postoperative Days 1, 2, 3, 4, 7, 8 and 14

ArmMeasureGroupValue (MEDIAN)
Experimental TreatmentDaily Worst Pain IntensityDay 15 units on a scale
Experimental TreatmentDaily Worst Pain IntensityDay 24.5 units on a scale
Experimental TreatmentDaily Worst Pain IntensityDay 34.3 units on a scale
Experimental TreatmentDaily Worst Pain IntensityDay 43 units on a scale
Experimental TreatmentDaily Worst Pain IntensityDay 71.8 units on a scale
Experimental TreatmentDaily Worst Pain IntensityDay 82 units on a scale
Experimental TreatmentDaily Worst Pain IntensityDay 142 units on a scale
Secondary

Opioid Consumption Day 7

The cumulative opioid use from the previous 24 hours measured in oxycodone equivalents as recorded on Day 7

Time frame: Day 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentOpioid Consumption Day 70 milligrams
Secondary

Worst Daily Pain Intensity 1st Week

The median of 5 daily worst (maximum) pain intensity scores for Days 1-4 and 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Time frame: Days 1-4 and 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentWorst Daily Pain Intensity 1st Week4.0 units on a scale
Secondary

Worst (Maximum) Daily Pain Intensity Day 7

The worst pain intensity score on Day 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst)

Time frame: Day 7

ArmMeasureValue (MEDIAN)
Experimental TreatmentWorst (Maximum) Daily Pain Intensity Day 71.8 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026